Andrew Dudum Sells 128,127 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the sale, the chief executive officer now directly owns 173,655 shares of the company’s stock, valued at $5,900,796.90. This trade represents a 42.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29.
• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.22, for a total transaction of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $33.85 on Thursday. The firm’s 50-day moving average is $38.88 and its 200-day moving average is $28.52. The company has a market cap of $7.52 billion, a price-to-earnings ratio of 76.94 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HIMS. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Needham & Company LLC boosted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Piper Sandler increased their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Bank of America boosted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research note on Tuesday. Finally, BTIG Research initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $37.31.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. boosted its position in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health during the fourth quarter worth about $38,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.